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sinus folding’ (VSF) and mural cell drop-out occur distinctly in a spatiotemporal
manner in the rapidly growing mouse uterus during early pregnancy— just after
implantation but before placentation. Decidual angiogenesis is mainly regulated
through VEGF-A secreted from the progesterone receptor (PR)-expressing
decidual stromal cells which are largely distributed in the anti-mesometrial
region (AMR). In comparison, P4-PR-regulated VEGF-A-VEGFR2 signalling, ligand-
independent VEGFR3 signalling and uterine natural killer (uNK) cells positively
and coordinately regulate enlargement and elongation of VSF. During the
postpartum period, Tie2 signalling could be involved in vascular maturation at
the endometrium in a ligand-independent manner, with marked reduction of
VEGF-A, VEGFR2 and PR expressions. Overall, we show that two key vascular
growth factor receptors — VEGFR2 and Tie2 — strikingly but differentially
regulate decidual angiogenesis and vascular remodelling in rapidly growing and
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Each organ has distinct and unique neovascularization and
vascular remodelling processes for its growth, maintenance and
regeneration. Understanding the regulation of organotypic
neovascularization and vascular remodelling is essential and
provides insight into how to control these processes. Neo-
vascularization (including vasculogenesis and angiogenesis)
and vascular remodelling (including branching, enlargement
and network formation) are known to be majorly regulated by
two key growth factor families and their cognate receptors:
vascular endothelial growth factor (VEGF) and its receptor
(VEGFR) and angiopoietin (Ang) and the Tie2 receptor
(Augustin et al, 2009; Carmeliet, 2003; Chung &
Ferrara, 2011; Lohela et al, 2009). However, we are only
beginning to understand the organ‐speciﬁc roles of these
molecules.s is an open access article under
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1416The uterus is an exceptional organ, showing enormous cyclic
neovascularization and vessel regression during the uterine
cycle period, while neovascularization is mostly at rest during
premenstrual and postmenopausal stages of life. In early
pregnancy, the rapid growth of the uterus during embryo
implantation and the early post‐implantation period is accom-
panied by profound neovascularization and vascular remodel-
ling to deliver sufﬁcient oxygen and nutrients to the uterus as
well as to the embryo until the placenta becomes structurally and
functionally competent (Cha et al, 2012; Dey et al, 2004; Wang &
Dey, 2006). Implantation of an embryo induces rapid prolifera-
tion and differentiation of uterine stromal cells, forming a new
structure, the decidua (Cha et al, 2012; Dey et al, 2004; Ramathal
et al, 2010; Wang & Dey, 2006). One salient feature of decidua
formation is ‘decidual angiogenesis’, a marked increase in
uterine neovascularization that is promoted during early
pregnancy by factors secreted from decidual stromal cells
(DSCs) and the adjacent immune cells, such as uterine natural
killer (uNK) cells and dendritic cells (uDCs) (Blois et al, 2011;
Demir et al, 2010; Plaisier, 2011; Ramathal et al, 2010; Rowe
et al, 2003; Smith, 2001; Torry et al, 2007; Zhang et al, 2011).
Decidual angiogenesis forms a new vascular network that serves
as the ﬁrst exchange apparatus between maternal circulation
and the developing embryo, and thus is a crucial and
fundamental process for embryonic survival and successful
pregnancy. The steroid hormones progesterone (P4, pregn‐4‐
ene‐3,20‐dione) and estrogen (E2, 17b‐estradiol) are secreted
from ovaries and, through binding of the progesterone receptor
(PR) and estrogen receptor (ER), play orchestral roles in
regulating decidua formation during early pregnancy (Carson
et al, 2000; Conneely et al, 2003; Wetendorf & DeMayo, 2012).
Two decades ago, Keshet’s research group ﬁrst suggested that
high VEGF‐A expression in DSCs could be regulated by steroid
hormones (Shweiki et al, 1993). Since then, the roles of P4, E2
and their receptors in decidual angiogenesis have been studied,
but they appear to vary depending on species, timing and
experimental design (Das et al, 2009; Girling et al, 2007;
Heryanto & Rogers, 2002; Walter et al, 2005), and thus have not
yet been ﬁrmed established. Moreover, it is unknown how P4
and E2 affect the VEGF‐A‐VEGFR2 system in a spatiotemporal
manner to promote decidual angiogenesis during early
pregnancy.
It is known that the expressions of VEGF‐VEGFR and Ang‐Tie2
in the uterus dynamically change during the estrus cycle period,
embryo implantation and the early post‐implantation period
(Chakraborty et al, 1995; Demir et al, 2010; Plaisier, 2011; Rowe
et al, 2003; Smith, 2001; Torry et al, 2007). Functional studies
indicate that VEGF‐A — a major angiogenic growth factor and a
ligand to VEGFR2 — is involved in regulating uterine
angiogenesis and implantation in rodents and nonhuman
primates (Heryanto & Rogers, 2002; Klauber et al, 1997;
Sengupta et al, 2007; Walter et al, 2005). Moreover, a recent
study using speciﬁc blockades reported that VEGFR2 signalling
(but not VEGFR1 signalling) is critical in decidual angiogenesis,
vascular remodelling and pregnancy progression, while VEGFR3
signalling may moderately contribute to decidual angiogenesis
but has no effect on early pregnancy progression (Douglas 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.et al, 2009). It remains poorly understood where and how
VEGF‐A is expressed and regulated, and how VEGF‐A–VEGFR2
signalling drives decidual angiogenesis and vascular remodelling
in a spatiotemporal manner during early pregnancy. Moreover,
little is known regarding to what extent the driving force for
decidual angiogenesis and vascular remodelling during early
pregnancy can be attributed to VEGF‐C/D‐VEGFR3 signalling.
Furthermore, during the postpartum period, the uterus under-
goes rapid shrinkage with strong contractile activity and
endometrium normalization, but little is known about the exact
characteristics and regulations of vascular remodelling and
regression in the endometrium.
In the present study, the spatiotemporal changes of decidual
angiogenesis and vascular remodelling in the mouse uterus
during the post‐implantation period (from 4.5 to 8.5 days post
coitum (dpc) before active placental development) and during
the postpartum period were determined. We shed a light on the
feature and regulation of VSF, arterio‐venous vascular shunt or
reservoir, which is markedly enlarged and elongated during this
period. We found that the VEGF‐A/VEGFR2 system plays a
critical role in decidual angiogenesis and VSF remodelling, and
thus we tried to clarify how VEGF‐A expression is regulated in
DSCs. We found that the P4‐PR axis is a main regulator of
VEGF‐A expression in DSCs, while VEGFR3 and uNK cells are
also involved in VSF remodelling. Moreover, when we
determined how blood vessels are regressed and undergoing
vascular maturation in the endometrium during the postpartum
period, we unexpectedly found indications of the ligand‐
independent involvement of Tie2 signalling with marked
reductions of expressions of VEGF‐A, VEGFR2 and PR, and
restoration of mural cell coverage on the blood vessels.RESULTS
Dynamic but distinct uterine angiogenesis and vascular
remodelling at different regions during early pregnancy
Taking advantage of profound morphological changes in the
mouse uterus during early pregnancy (Supporting Information
Fig S1A and B), we analysed structural changes in blood vessels
and the molecular regulation of angiogenesis and vascular
remodelling in the uterus from 4.5 to 8.5 dpc, which is just after
implantation (4.0–4.5 dpc) but prior to initial placenta estab-
lishment (9.5–10.5 dpc). To distinguish maternal uterine blood
vessels from placental blood vessels, a set of B6 females were
mated with syngeneic GFPþ males, and the pregnant uteri were
obtained at 4.5, 6.5 and 8.5 dpc. The GFPþ embryos were easily
distinguishable from the maternal uteri at each time point
(Fig 1A and Supporting Information Fig S2A). The embryo‐
derived placental cone was clearly demarcated on 8.5 dpc, when
the umbilical and vitelline vessels emerged (Fig 1A). Taking
advantage of the clear demarcation, only uterine blood vessels
were convincingly highlighted by immunovisualization of
CD105 (endoglin) or CD31 in mid‐sectioned uteri (Fig 1A).
Variable‐sized VSFs (Chandana et al, 2010) were distributed
symmetrically in the central region (CTR) andwere enlarged and
elongated over time, whereas ﬁne mesh‐like blood vessels wereEMBO Mol Med (2013) 5, 1415–1430
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1418arrayed in the anti‐mesometrial region (AMR) (Fig 1A and
Supporting Information Fig S1 and 2). Closer observations of the
CTR revealed that the sprouting process was most active at
4.5 dpc, while enlargement and elongation of VSF (EEVSF) and
intussusception of blood vessels (Burri et al, 2004) were
dominant from 6.5–8.5 dpc (Fig 1B–E, G and H). At 6.5 dpc,
number of vascular sprouts (>20 mm in length) in the CTR was
increased by 14.9‐ and 2.8‐fold compared to those in the estrus
stage of non‐pregnancy (ENP) and the AMR (Fig 1I). Moreover,
number of intussusceptive blood vessels in the CTR was
increased by 7.4‐ and 2.4‐fold compared to those of the ENP and
the AMR (Fig 1J). At 6.5 dpc, proliferating phosphohistone H3
(PH3)þ endothelial cells (ECs) in the AMR were elevated by 4.2‐
and 1.5‐fold compared to those of the ENP and the MR (Fig 1F
and K). Time‐series analyses indicated that, compared to at
4.5 dpc, the number of large‐sized (diameter, >300 mm) VSF in
the CTR was markedly increased at 6.5 and 8.5 dpc, and blood
vessel densities in the AMRwere increased by 2.0‐ and 2.2‐fold at
6.5 and 8.5 dpc, respectively (Fig 1L, M and Supporting
Information Fig S1B). Moreover, the majority of blood vessels
in the uteri were covered with a‐smooth‐muscle actin (a‐SMA)‐
positive mural cells at 4.5 dpc; however, at 6.5 and 8.5 dpc, this
coverage had largely disappeared in most regions, except the
surrounding of spiral arteries (Supporting Information Fig S2B).
Thus, profound variable decidual angiogenesis; sprouting,
intussusception and networking angiogenesis with high EC
proliferation, and dynamic vascular remodelling; EEVSF and
mural cell drop‐out occurred distinctly at different regions in the
growing uterus during the post‐implantation period before
placenta establishment.
The VEGF‐A‐VEGFR2 system plays a major role in decidual
angiogenesis and EEVSF during early pregnancy
These initial observations led us to investigate how dynamic
vascular remodelling is ﬁnely regulated by key angiogenic
growth factors during early pregnancy. DSCs are a main resource
for a battery of angiogenic growth factors (Demir et al, 2010; Dey
et al, 2004; Plaisier, 2011; Rowe et al, 2003; Torry et al, 2007);
therefore we compared relative expression levels of the growth
factors in primary cultured DSCs to those of other primary
cultured stromal cells, such as cardiac ﬁbroblasts, retinal
astrocytes, and mouse embryonic ﬁbroblasts (MEFs). Quantita-Figure 1. Distinct regional differences in uterine vascular features during ea
A. Image showing CD31þ blood vessels (BVs) and GFPþ embryo in the uterus a
region (MR) and anti-mesometrial region (AMR). The MR is subdivided into
folding. Scale bar, 500 mm.
B–F. Images showing CD31þ uterine BVs. Sprouting (B, arrows), variable-sized VSF
the MR, whereas fine vascular network (E) and PH3þ proliferating ECs (F,
G, H. Scanning electron micrographs showing vascular lumens (VL) without and w
bars, 5 mm.
I, J. Comparisons of numbers of vascular sprouts and intussusceptions in the uter
AMR at 6.5 dpc. Each group, n ¼ 5–6. p < 0.002 versus ENP.; #p < 0.001
K. Comparisons of number of PH3þ/CD31þ proliferative ECs in the uterine end
Each group, n ¼ 5–6 p < 0.0003 versus ENP; #p ¼ 0.0014 versus MR by
L, M. Comparisons of CD31þ BV densities (BVD, %) in the AMR and numbers of d
n ¼ 5–6. p < 0.02 versus ENP.; #p < 0.02 versus 4.5 dpc by one-way ANO
 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.tive real‐time PCR analyses revealed that, in DSCs compared to
in other stromal cells, VEGF‐A mRNA expression was higher,
and mRNA expressions of placental growth factor (PlGF),
angiopoietin‐1 (Ang1), angiopoietin‐2 (Ang2), VEGF‐C, PDGF‐A
and TGF‐b1 were slightly higher, similar, or lower (Fig 2A).
Based on these ﬁndings, we examined role of VEGF‐A in
decidual angiogenesis and vascular remodelling in the pregnant
uteri by treatment of VEGF‐Trap (simultaneous blockade of
VEGF‐A and PlGF (Holash et al, 2002) at 4.5 dpc. This treatment
resulted in profoundly pruned vascular structures and reduced
blood vessel densities in both the CTR (35%) and AMR (53%) at
6.5 dpc compared to those of control treated mice (Fig 2B–D).
Furthermore, embryo resorption was observed in close to half of
the VEGF‐Trap‐treated mice (Supporting Information Table S1).
We also noted that VEFG‐Trap treatment markedly decreased
the number of large‐sized (>500 mm) VSF in the CTR (85%)
(Fig 2C and E). Following VEGF‐Trap treatment at 6.5 dpc, we
observed similar reductions in blood vessel densities and
numbers of large‐sized VSF at 8.5 dpc, but without signiﬁcant
embryo resorption (Supporting Information Fig 3A–C and
Supporting Information Table S1). We next used VEGFR1‐
tyrosine kinase‐deﬁcient (VEGFR1TK/) mice to investigate the
role of PlGF, which only binds to VEGFR1 (Hiratsuka et al, 1998).
In contrast to the ﬁndings with VEGF‐Trap, blood vessel
densities and vascular structures did not differ between wild‐
type and VEGFR1TK/ mice at 6.5 dpc (Fig 2B–D). Moreover,
expressions of Ang1, Ang2 and Tie2 were detectable but
relatively low in the DSCs and vasculatures of uteri at 6.5 dpc
(data not shown). These data indicated that decidual angiogen-
esis during early pregnancy was mainly regulated through
VEGF‐A/VEGFR2 signalling, not through PlGF/VEGFR1 or
Ang‐Tie2 signalling. Moreover, VEGF‐A‐VEGFR2 signalling is
positively involved in EEVSF.
VEGF‐A expression of DSCs is regulated in a spatiotemporal
manner, but is independent of hypoxia
To explore the regulatory role of VEGF‐A/VEGFR2 signalling in
decidual angiogenesis and EEVSF, we ﬁrst examined VEGF‐A
expression in the pregnant uterus of VEGF‐A‐LacZ reporter
(VEGF‐Aþ/LacZ) mice (Miquerol et al, 2000). The spatial pattern
of VEGF‐A expression in the uterus was quite striking at 6.5 dpc,
in that it was highly expressed in DSCs at the secondary decidualrly pregnancy.
t 8.5 dpc. Dotted-line divides the mid-sectioned uterus into the mesometrial
the central region (CTR) and uterine lumen region (ULR). VSF, vascular sinus
(C) and intussusceptive pillar (D, white arrowheads) are frequently present in
yellow arrowheads) are present in the AMR at 6.5 dpc. Scale bars, 50 mm.
ith abundant intussusceptive pillars (arrowheads) in the MR at 6.5 dpc. Scale
ine endometrium of the estrus stage of non-pregnancy (ENP), and the CTR and
versus MR by unpaired t test.
ometrium of the ENP, and the MR and AMR at 6.5 dpc in a given area (cm2).
unpaired t test.
ifferent sized VSFs in the MR at ENP, and 4.5, 6.5, and 8.5 dpc. Each group,
VA.
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Figure 2. VEGF‐A‐VEGFR2 system is a key regulator of decidual angiogenesis and EEVSF during early pregnancy.
A. Comparisons of mRNA levels of genes regulating angiogenesis in primary cultured DSCs, cardiac fibroblasts, retinal astrocytes and mouse embryonic
fibroblasts (MEFs). Data are presented as relative folds to the levels of cardiac fibroblasts after normalization with GAPDH. Each group, n ¼ 4. p < 0.05
versus cardiac fibroblasts; #p < 0.04 versus retinal astrocytes; $p < 0.03 versus MEFs by one-way ANOVA.
B. Representative images showing CD31þ BVs in the uteri at 6.5 dpc of control, VEGF-Trap treated and VEGFR1TK/. Scale bars, 500 mm. UL, uterine lumen.
C. Magnified images showing endometrial CD31þ BVs in the ULR, CTR of the MR and AMR. Scale bars, 100 mm.
D, E. Comparisons of CD31þ BVD (%) in the ULR, CTR and AMR and numbers of different sized VSFs in the CTR at 6.5 dpc. Each group, n ¼ 3–4. p < 0.04 versus
Control by one-way ANOVA.
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Minah Kim et al.zone of the AMR and in surrounding regions of the enlarged VSF,
but its expression was largely absent or barely detectable in most
regions of the MR and ENP (Fig 3A and B). Immunohistochemi-
cal analysis revealed that secreted VEGF‐A appeared to be bound
to vascular matrix or VEGFR2 at the secondary decidual zone of
the AMR (Supporting Information Fig 3D). In comparison,
during early pregnancy, VEGFR2 was expressed in all vascu-
latures of most regions, including endometrium and myome-
trium (Fig 3C and Supporting Information Fig 3E). These data
implied that VEGF‐A expression was ﬁnely regulated in a
spatiotemporal manner, and that VEGFR2 signalling in the
pregnant uterus could be activated through both ligand‐
dependent and ligand‐independent manners. Because hypoxia
is the strongest stimulus for VEGF‐A expression (Ferrara, 2004),EMBO Mol Med (2013) 5, 1415–1430 we determined spatial correlations among VEGF‐A expression,
hypoxia extent, and expressions of hypoxia‐inducible factor‐1a
(HIF‐1a) and HIF‐2a in the uteri at 6.5 dpc. Hypoxia extent,
HIF‐1a expression and HIF‐2a expression were not correlated
with VEGF‐A expression; however, there were spatial correla-
tions between hypoxia and expressions of HIF‐1a and HIF‐2a at
the primary decidual zone (Fig 3D–F). Thus, regulation of
VEGF‐A expression in the DSCs of the pregnant uterus seemed to
be independent of hypoxia.
P4‐PR axis positively regulates VEGF‐A expression of DSCs for
decidual angiogenesis and EEVSF
We next examined the spatial correlation between VEGF‐A
expression and PR expression since ovary‐secreted P4 and the2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1419
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1420DSC‐localized PR axis are known to play critical roles in decidua
formation and angiogenesis during early pregnancy (Conneely et
al, 2003; Dey et al, 2004; Lydon et al, 1995; Wetendorf &
DeMayo, 2012). Indeed, PR was mainly expressed in DSCs of the
CTR and AMR, and expressions of VEGF‐A and PR spatiotem-
porally coincided (Fig 4A).We also noted that two forms of PR—
PR‐A and PR‐B (Conneely et al, 2003)—were highly detected in
the normal uterus compared to in other organs, including
mammary gland, ovary, brain and kidney; their levels were up‐
regulated at 6.5 dpc, but largely reduced at postpartum day 2.5
(PD 2.5) (Fig 4B). In primary cultured DSCs, mRNA expression
of the major form of VEGF‐A (VEGF‐A164) was increased by
addition of 10 mM P4 (Fig 4C). Compared to control PR‐Cre‐
VEGF‐Aþ/þ mice at 6.5 dpc, in PR‐Cre‐VEGF‐Aþ/ﬂox mice (with
one copy of the VEGF‐A gene depleted in the DSCs), blood
vessels were moderately pruned, blood vessel densities were
reduced in both the CTR (26%) and AMR (32%) regions but
not in the uterine lumen region (ULR), and the numbers of
300–500 mm (44%) and >500 mm (45%) VSF were reduced in
the CTR (Fig 4D–F). Conversely, supplemental P4 (20 mg/kg) 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.administered at 4.5 and 5.5 dpc increased blood vessel densities
in both the CTR (21%) and AMR (18%) but not in the ULR, and
increased numbers of 300–500 mm (41%) and >500 mm (36%)
VSF in the CTR compared to in control mice at 6.5 dpc (Fig 4G–
I). Blockade of VEGF‐A by administration of VEGF‐Trap (twice,
at 4.5 and 5.5 dpc) completely abrogated the P4‐induced
increases in blood vessel densities and EEVSF (Fig 4G–I),
indicating that the P4‐induced decidual angiogenesis and EEVSF
in the pregnant uterus were mainly mediated through up‐
regulation of VEGF‐A expression in DSCs.
To verify this functional role of the P4‐PR‐VEGF‐A axis in
decidual angiogenesis and EEVSF, we performed a pharmaco-
logical blockade of PR in pregnant mice by a single administra-
tion of RU486 (8.0 mg/kg) at 5.5 dpc, determined based on our
preliminary trials for selection of timing and dosage of RU486. As
expected, administration of RU486 at 5.5 dpc reduced expres-
sions of VEGF‐A and VEGFR2, number of CD31þ/CD45 EC
(62%), blood vessel densities in both the CTR (38%) and AMR
(53%) but not in the ULR, numbers of 300–500 mm (48%) and
>500 mm(74%) VSF in the CTR, and EC proliferation rate (88%)EMBO Mol Med (2013) 5, 1415–1430
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week-old non-pregnant female mouse. Loading of similar amount of protein for each sample is verified by a similar intensity of b-actin signal.
C. Increase of VEGF-A mRNA expression in the primary cultured DSCs by P4 (10 mM) stimulation for 12 and 24 h. Data are presented as relative fold to the
control (C) after normalization with GAPDH. Each group, n ¼ 3. p ¼ 0.0232 versus C by unpaired t test.
D. Images showing CD31þ BVs in the ULR, CTR and AMR of control PR-Cre-VEGF-Aþ/þ mice (PRCreVAþ/þ) and PR-Cre-VEGF-Aþ/fl (PRCreVAþ/fl) mice at 6.5 dpc.
Scale bars, 100 mm.
E, F. Comparisons of CD31þ BVD (%) in the ULR, CTR and AMR, and numbers of different sized VSFs in the CTR of control PRCreVAþ/þ and PRCreVAþ/fl mice at
6.5 dpc. Each group, n ¼ 3. p < 0.03 versus PRCreVAþ/þ by one-way ANOVA.
G. Images comparing CD31þ BVs in the ULR, CTR and AMR at 6.5 dpc treated P4 and P4 plus VEGF-Trap. Scale bars, 100 mm.
H, I. Comparisons of CD31þ BVD (%) in the ULR, CTR and AMR, and numbers of different sized VSFs in the CTR at 6.5 treated with control, P4, VEGF-Trap and P4
plus VEGF-Trap. Each group, n ¼ 3. p < 0.05 versus control by one-way ANOVA.
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Minah Kim et al.in the AMR in the treated uteri compared to in the controls at
6.5 dpc (Fig 5); RU486 treatment also led to embryo resorption in
almost 30% of mice (Supporting Information Table S1). To
exclude possible contribution of ovarian hormones other than
progesterone in decidual angiogenesis and EEVSF, we con-
ducted a bilateral ovariectomy with supplementation of P4
according to previous reports (Douglas et al, 2009; Walter et al,
2005). At 6.5 dpc, we found no signiﬁcant differences of
vascular densities and structures in the pregnant uteri in theEMBO Mol Med (2013) 5, 1415–1430 ovariectomized P4‐supplemented mice compared to in sham‐
operated control mice (Supporting Information Fig S4A–C). To
determine the effect of E2 on decidual angiogenesis and EEVSF,
we administrated the ER inhibitor ICI 182780 (1 mg/kg) at
5.5 dpc. At 6.5 dpc, we found no signiﬁcant differences in the
vascular densities and structures in the pregnant uteri of ICI
182780‐treated mice compared to control‐treated mice (Support-
ing Information Fig S4D–F). Thus, the ovary‐secreted P4/PR‐
expressing DSC axis positively and spatially governed VEGF‐A2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1421
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Figure 5. Pharmacologic blockade of PR with RU486 negatively regulates VEGF‐A expression in DSCs for decidual angiogenesis and EEVSF. The pregnant
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B. Semi-quantitative RT-PCR showing mRNA expressions of VEGF-A and VEGFR2 (VR2). Each line indicates gene transcript of VEGF-A120, VEGF-A164 and
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C. FACS analysis showing CD31þ/CD45 EC populations from the endometrium. Each group, n ¼ 4.
D. Images comparing CD31þ BVs in the ULR, CTR and AMR. Scale bars, 100 mm.
E, F Comparisons of CD31þ BVD (%) in the ULR, CTR and AMR, and numbers of different sized VSFs in the CTR. Each group, n ¼ 4. p < 0.01 versus Control by one-
way ANOVA.
G. Images showing PH3þ proliferative ECs (yellow arrowheads) in the AMR. Scale bars, 100 mm.
H. Comparison of number of PH3þ/CD31þ proliferative ECs in a given area (cm2) of the endometrium. Each group, n ¼ 4 p ¼ 0.001 versus C by unpaired t test.
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1422expression in DSCs for decidual angiogenesis at the AMR and
EEVSF, particularly at the CTR, during early pregnancy after
implantation.
Possible involvement of VEGFR3 and uNK cells, but not uDCs, in
EEVSF during post‐implantation period
VEGFR3, the cognate receptor of VEGF‐C/D, together with
VEGFR2, was strongly expressed in the ECs of the VSF and the
Prox‐1þ lymphatic vessels of early pregnant uteri (Fig 6A and
Supporting Information Fig S5), although VEGF‐C expression
was barely detectable in the adjacent tissues (Fig 6B); therefore,
we next determined the role of VEGFR3 in vascular remodelling
by inducing VEGF‐C/D blockade through twice administrations
of sVEGFR3‐Fc (25 mg/kg) at 6.5 and 7.5 dpc. Vascular densities
and structures in three different regions at 8.5 dpc were not
distinguishable between sVEGFR3‐Fc‐ and Fc‐administered mice 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.(Fig 6C–E). Thus, VEGFR3may be involved in EEVSF in a ligand‐
independent manner (Benedito et al, 2012) or via heterodime-
rization with VEGFR2 (Nilsson et al, 2010; Wang et al, 2010). To
determine the role of uDCs on vascular remodelling, CD11c:DTR
transgenic mice (Jung et al, 2002) were treated with diphtheria
toxin (DTx) at 5.5 or 6.5 dpc (Fig 7A). Vascular densities and
structures in three different regions at 6.5 or 8.5 dpc were not
distinguishable between uDC‐depleted mice and uDC‐intact
mice (Fig 7A–C). However, we detected impaired vascular
remodelling and embryonic resorption at 6.5 dpc when DTx was
administrated at 4.5 dpc (Supporting Information Table S1),
showing phenotypes consistent with those previously reported
(Plaks et al, 2008). These results indicated that uDCs had a
crucial role in establishing embryo implantation, but not in
the uterine vascular remodelling occurring after successful
embryo implantation. To determine the role of uNK cells‐secretedEMBO Mol Med (2013) 5, 1415–1430
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Minah Kim et al.growth factors on vascular remodelling, uNK cells were
depleted by administration of anti‐NKG2D antibody (7.5 mg/kg)
at 6.5 and 7.5 dpc (Fig 7D). Compared to the control, the uNK
cells‐depleted mice exhibited reduced blood vessel densities
(22%) and reduced numbers of large (>500 mm) VSF in the CTR
(68%) at 8.5 dpc, although no signiﬁcant differences in vascular
densities and expressions of VEGFR2 and VEGFR3 were detected
in the ULR and AMR (Fig 7D–F and Supporting Information
Fig S6). These results indicated that uNK cells were involved
in EEVSF.
Dynamic postpartum changes in expressions of VEGF‐A, PR and
angiogenic growth factor receptors, and in mural cell coverage
of uterine blood vessels
In contrast to in early pregnancy — after delivery, uterine sizes
were sharply decreased and the endometrial blood vessels were
regressed and maturated (Supporting Information Fig S7A and
B) in parallel with sharp decreases in blood progesterone level
(Nadal et al, 2009). The number of blood vessels in the
endometrium was relatively high at PD 0.5, markedly reduced atEMBO Mol Med (2013) 5, 1415–1430 PD 2.5, and rebounded at PD 4.5 up to the levels of ENP (Fig 8A
and B). Concomitantly, VEGF‐A and both forms of PR in the
DSCs were sharply reduced in the postpartum uteri (Figs 4B and
8C). The number of caspase‐3þ apoptotic ECs in the endometri-
um was markedly increased in PD 2.5 compared to ENP and
6.5 dpc (Fig 8D and G). Furthermore, expressions of VEGFR2
and VEGFR3 in the endometrial blood vessels were markedly
reduced to levels similar to those of ENP (Fig 8E, F and H). In
contrast, compared to 6.5 dpc, Tie2 expression and coverage of
a‐SMAþ mural cells on CD31þ blood vessels were 2.3‐ and 7.8‐
fold higher in PD 0.5, and gradually increased at PD 2.5 and 4.5
(Fig 8I–L). In particular, Tie2 expressions on blood vessels at PD
2.5 and 4.5 were 7.0‐fold higher than that in the ENP (Fig 8K).
These intriguing ﬁndings led us to examine the postpartum role
of the Ang‐Tie2 system in uteri. However, expressions of Ang1
and Ang2 were barely detectable in postpartum uteri (data not
shown). Blockade of Ang‐Tie2 signalling by administration of
sTie2‐Fc (25 mg/kg) at PD 0.5 and 1.5 did not induce any
signiﬁcant changes in vascular density, Tie2 expression, or
coverage of a‐SMAþ mural cells on CD31þ blood vessels at PD2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1423
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14242.5 in the treatment group compared with control Fc (Supporting
Information Fig 7C–E). Thus, Tie2 may be involved in mural
cell coverage and vessel regression and maturation in a
ligand‐independent manner in uteri during the postpartum
period.DISCUSSION
In the present study, immunolocalization of blood vessels
revealed that dynamic and variable decidual angiogenesis
(including sprouting, intussusception and networking) and
tremendous vascular remodelling (EEVSF and mural cell drop‐
out) occur distinctly at different regions in a temporal manner in
the growing uterus during early pregnancy (Fig 9). In contrast, 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.during the postpartum period, blood vessels in the endometrium
rapidly regressed and maturated, with restoration of mural cell
coverage. These observations led us to investigate the ﬁne
regulation of such angiogenesis and vascular remodelling by a
key angiogenic growth factor system VEGF‐VEGFR during these
periods. Our spatiotemporal analyses indicated that decidual
angiogenesis was mainly governed through P4‐PR/VEGF‐A‐
VEGFR2 signalling, but not through PlGF/VEGFR1 or Ang‐Tie2
signalling, during early pregnancy (Fig 9). We further found that
the P4‐PR/VEGF‐A‐VEGFR2 signalling pathway, ligand‐indepen-
dent VEGFR3 signalling, and uNK cells positively regulate EEVSF
(Fig 9). Disturbances of blood supply into the early pregnant
uterus by impairments of these signalling pathways and cellular
coordination could be associated with the ﬁrst‐trimester
miscarriage, preeclampsia, placental failure and intrauterineEMBO Mol Med (2013) 5, 1415–1430
Figure 8. Dynamic changes of vascular density, expressions of VEGF‐A, PR and angiogenic growth factor receptors, and mural cell coverage onto blood
vessels in the postpartum uteri.
A. Images showing CD31þ BVs in the endometrium at PD 0.5, 2.5 and 4.5.
B, C. Comparisons of CD31þ BVD (%) and expressions of VEGF-A and PR in the endometrium of ENP, 6.5 dpc, and PD 0.5, 2.5 and 4.5. Each group, n ¼ 4 p < 0.05
versus ENP by one-way ANOVA.
D–F Images showing caspase-3þ ECs (yellow arrowheads) and expressions of VEGFR2 and VEGFR3 in the endometrium at ENP, 6.5 dpc and PD 2.5.
G, H. Comparison of number of caspase-3þ/CD31þ ECs and expressions of VEGFR2 and VEGFR3 (relative folds to the levels of ENP) in the endometrium in a given
area (cm2) at ENP, 6.5 dpc and PD 2.5. Each group, n ¼ 4 p < 0.005 versus ENP by one-way ANOVA.
I, J. Images showing Tie2 expressions and a-SMAþ coverage on the CD31þ BVs in the endometrium at PD 0.5, 2.5 and 4.5.
K, L. Comparisons of Tie2 expression and a-SMAþmural cell coverage on the CD31þ BVs (%) in the endometrium of ENP, 6.5 dpc, and PD 0.5, 2.5 and 4.5. Each
group, n ¼ 4 p < 0.02 versus ENP; #p < 0.04 versus 6.5 dpc; $p < 0.0004 versus PD 0.5 by one-way ANOVA. UL, uterine lumen. All scale bars, 100 mm.
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Minah Kim et al.growth restriction of births (Plaisier, 2011). Intriguingly, during
the postpartum period, Tie2 signalling could be involved in
vascular maturation at the endometrium in a ligand‐independent
manner. Postpartum hemorrhage can be caused by an
impairment of the Tie2 signalling in the postpartum uterus
(Oyelese & Ananth, 2010).
Although uterine blood vessels undertake the most dynamic
vascular remodelling and angiogenesis during pregnancy, their
spatiotemporal regulation within the uterus is poorly under-
stood. In this study, we made several key ﬁndings and clariﬁed
their underlying mechanisms using genetically modiﬁed mice
and pharmacological interventions. Firstly, our analyses
revealed that VSF is a dilated arterio‐venous vascular shunt,EMBO Mol Med (2013) 5, 1415–1430 which is enlarged and elongated rapidly during the early
pregnancy, and thus it has a bulk of blood ﬂow for the growing
uterus and embryo. VSF could be a transient blood reservoir for
immediate need of blood to the growing embryo in emergency
situations prior to placenta formation. Moreover, EEVSF could
be a cue for spiral artery modiﬁcation and placenta formation.
Impairment of EEVSF could lead to trophoblast‐independent
preeclampsia, which produces hypertension and proteinuria
during pregnancy, and even pregnancy failure in severe case
(James et al, 2010; Pijnenborg et al, 2006; Plaisier, 2011).
Secondly, among several angiogenic growth factors, we found
that VEGF‐A played a major role in decidual angiogenesis and a
moderate role in EEVSF in the uterus during early pregnancy.2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1425
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1426Strikingly, VEGF‐A was highly expressed in DSCs located in the
AMR and the VSF area at CTR but not in the MR. Its expression
coincided exactly with PR expression, but not with hypoxia or
HIF expressions. At that time, the level of circulating P4 that is
secreted mainly from ovary is rapidly increased (Nadal
et al, 2009), and VEGFR2 is already highly expressed in the
uterine blood vessels. Based on these ﬁndings, we propose that
the P4‐PR‐VEGF‐A axis mainly governs decidual angiogenesis
and partially governs EEVSF. It remains to be elucidated which
upstream regulator controls the expression of PR in DSCs that are
located in the AMR and the VSF area at CTR. Our data suggest
that putative vascular remodelling factors secreted from uNK
cells distributed in the VSF region could play a coordinated role
in EEVSF during early pregnancy. Consistent with a previous
report (Plaks et al, 2008), our analyses of the temporal role of
uDCs indicated that uDCs are crucial for embryo implantation
and its associated vascular remodelling in the pregnant uteri
during 3.5–5.5 dpc. However, we found that they are no longer
crucial in the vascular remodelling including EEVSF in the
pregnant uteri during 6.5–8.5 dpc after the successful embryo
implantation.
Thirdly, during early pregnancy, VEGFR2 is highly expressed
in most blood vessels regardless of the uterus region, while
VEGFR3 is selectively and highly expressed in the ECs of VSF at
the decidualization zone, and can be a biomarker of VSF. The
VSF abruptly receives increased blood ﬂow during early
pregnancy, requiring a markedly increased mechanical stretch-
ing, which may induce VEGFR3 activation (Planas‐Paz
et al, 2012). Nevertheless, given that VEGF‐C expression is
relatively low or absent surrounding the VSF and that blockade 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.of VEGF‐C and VEGF‐D did not change EEVSF, we propose that
VEGFR3 could be involved in EEVSF in a mechano‐transduction
manner (Planas‐Paz et al, 2012) and/or a ligand‐independent
manner, as has been observed in the blood vessels of growing
retina (Benedito et al, 2012). Although the anti‐VEGFR3
antibody did not disrupt pregnancy progression (Douglas
et al, 2009), investigating the exact role of VEGFR3 in EEVSF
will require further studies involving the genetic deletion of
VEGFR3 or pharmacological inhibition of VEGFR3 kinase
activity in the VSF.
Finally, our spatiotemporal analyses of the postpartum period
uncovered several novel and intriguing ﬁndings on regression
and maturation of blood vessel in the uterus. Blood vessels were
pruned and regressed sharply with concomitant increase of
apoptosis in endometrial ECs. These could be caused by sharp
reductions of circulating P4 secreted from ovary (Nadal
et al, 2009), expressions of PR and VEGF‐A in the regressed
DSCs, and expressions of VEGFR2 and VEGFR3 in the ECs.
Intriguingly, the level of Tie2 expression and coverage of mural
cells on the blood vessels were much higher than those in ENP
and early pregnancy. Given that the levels of Ang1 and Ang2
were relatively low or absent around the Tie2‐expressing
blood vessels, and that sTie2 did not change the vascular
remodelling, Tie2 could be involved in mural cell coverage and
vascular regression and maturation in a ligand‐independent
manner in uteri during the postpartum period. To investigate the
role of Tie2 in blood vessels during the postpartum period,
further studies should involve genetic deletion of Tie2 in the
blood vessels or pharmacological inhibition of Tie2 kinase
activity.EMBO Mol Med (2013) 5, 1415–1430
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Minah Kim et al.In conclusion, our ﬁndings shed light on the previously
undeﬁned features and regulations of uterine angiogenesis and
vascular remodelling during early pregnancy and the postpar-
tum period. Dynamic but distinct decidual angiogenesis and
vascular remodelling at different regions occur in the early
pregnant uterus. In the rapidly growing uterus, P4‐PR‐regulated
VEGF‐A‐VEGFR2 signalling is a key regulator for decidual
angiogenesis, whereas P4‐PR‐regulated VEGF‐A‐VEGFR2 signal-
ling, VEGFR3 signalling and uNK cells coordinately control
EEVSF. In comparison, in the rapidly regressing uteri, Tie2
signalling could be involved in vascular maturation in a ligand‐
independent manner.MATERIALS AND METHODS
Mice
Animal care and experimental procedures were performed under
approval from the Animal Care Committees of KAIST and CHA
University. Speciﬁc pathogen‐free C57BL/6J, GFPþ (C57BL/6J),
ROSA26‐CreERT2 (C57BL/6J), CD11c:DTR (C57BL/6J). VEGFR1TK/ mice
(Hiratsuka et al, 1998), VEGF‐Aþ/LacZ mice (Miquerol et al, 2000),
VEGFR2þ/LacZ mice (Ema et al, 2006), VEGF‐Aﬂox/ﬂox mice (Gerber
et al, 1999), PR‐Cre mice (Soyal et al, 2005) and VEGF‐Cþ/LacZ mice
(Karkkainen et al, 2004) were transferred and bred in our pathogen‐
free animal facilities. VEGF‐Aþ/LacZ mice (Miquerol et al, 2000) have
elevated VEGF expression by 30UTR insertion of the IRES‐lacZ‐pA
sequence, resulting in increased stability of the VEGF‐A transcripts,
were used in this study to examine expression pattern of VEGF‐A since
they showed almost similar vascular structures and densities in the
uterine endometrium of both pregnancy and non‐pregnancy compared
to those of wild‐typemice.To deplete VEGF‐A in PRþ DSCs in the uterus,
VEGF‐Aﬂox/ﬂox mice were intercrossed with PR‐Cre mice. To deplete DCs
in a DTx‐dependent manner, 100 ng of DTx (2 ng/g of body weight,
Sigma–Aldrich) dissolved in PBS was injected into peritoneal cavity of
CD11c:DTR mice at indicated days. Wild‐type (designated as controls)
mice were treated with DT in the samemanner. Mice aged 7 to 8 weeks
were used for this study unless otherwise speciﬁcally indicated.
Females were mated with males, and the time that a vaginal plug was
found was designated 0.5 dpc. In addition, the morning after birth was
designated postpartum day (PD) 0.5. All mice were fed with ad libitum
access to standard diet (PMI Lab diet) and water. All mice were
anaesthetized by intramuscular injection of a combination of
anaesthetics (80 mg/kg of ketamine and 12 mg/kg of xylazine) before
being sacriﬁced.
Preparations and treatments of reagents
To produce recombinant proteins‐ dimeric‐Fc (Fc), VEGF‐Trap and
sVEGFR3‐Fc (consisting with the ﬁrst three immunoglobulin domains
of human VEGFR3 and the Fc‐domain of human antibody), stable CHO
cell lines that secrete these recombinant proteins were used as
previously described (Koh et al, 2010). Recombinant proteins in
supernatant were puriﬁed by column chromatography with Protein A
agarose gel (Oncogene) using acid elution. After puriﬁcation, the
recombinant proteins were quantiﬁed using the Bradford assay and
conﬁrmed by Coomassie blue staining after SDS‐PAGE. Proteins
were intraperitoneally injected by following dosages and schedules:EMBO Mol Med (2013) 5, 1415–1430 VEGF‐Trap (25 mg/kg) at 4.5, 5.5 or 6.5 dpc and sVEGFR3‐Fc (25 mg/
kg) at 6.5 and 7.5 dpc. As a control, Fc was injected in the samemanner.
P4 (Sigma–Aldrich) dissolved in peanut oil was intraperitoneally
injected in 0.5 mg per mouse at 4.5 and 5.5 dpc. RU486 (8 mg/kg;
Sigma–Aldrich) or ICI 182780 (1 mg/kg; Sigma–Aldrich) was intraperi-
toneally injected at 5.5 dpc. To eliminate uNK cells, anti‐NKG2D
antibody (7.5 mg/kg; MAB1547, R&D Systems) was intravenously
injected through tail vein at 6.5 and 7.5 dpc (twice a day). As a control,
Fc was injected in the same manner. All treated mice were sacriﬁced
and examined at indicated days.
Ovariectomy
To determine role of P4 upon exclusion of other ovarian hormones, a
combination of ovariectomy and P4 replacement was performed
according to procedures described previously (Douglas et al, 2009;
Walter et al, 2005) with some modiﬁcations. Brieﬂy, at 3.5 dpc, P4
(2.5 mg per mouse) was subcutaneously injected, and at 4 h later, the
bilateral ovariectomy was performed. From the next day, the mice were
treated with P4 (2.5 mg per mouse) twice a day in the same manner.
Histological analyses
On the indicated days, the mice were anaesthetized by intramuscular
injection of the combination of anaesthetics. Segments of the uterus
containing implanted embryos were ﬁxed in 1% paraformaldehyde,
embedded with tissue freezing medium (Leica) or parafﬁn, and
sectioned. Samples were blocked with 5% donkey (or goat) serum in
PBST (0.03% Triton X‐100 in PBS) and incubated for 3 h at room
temperature (RT) with the following primary antibodies and lectin:
anti‐CD105 (rat, cloneMJ7/18, eBioscience), anti‐CD31 (hamster, clone
2H8, Millipore, Billerica, MA, USA), anti‐PH3 (rabbit polyclonal,
Millipore), anti‐PR (rabbit polyclonal, Abcam), anti‐caspase‐3 (rabbit
polyclonal, R&D Systems), FITC‐conjugated anti‐a‐SMA (mouse, clone
1A4, Sigma–Aldrich), anti‐RFP (rabbit polyclonal, Abcam), anti‐VEGFR3
(goat polyclonal, R&D Systems), anti‐VEGF‐A (goat polyclonal, R&D
Systems), anti‐VEGFR2 (rabbit monoclonal, TO14, gifted by Dr. Rolf A.
Brekken), anti‐Prox‐1 (rabbit polyclonal, Relia Tech GmbH), anti‐CCR7
(rabbit polyclonal, Abcam), anti‐Tie2 (rabbit polyclonal, Santa Cruz
Biotechnology), anti‐angiopoietin‐1 (rabbit polyclonal, Ab Frontier),
anti‐Ang2 monoclonal (Aprogen) or biotin‐conjugated anti‐DBA lectin
(Sigma–Aldrich). After several washes, the samples were incubated for
2 h at RT with the following secondary antibodies: Cy3‐conjugated
anti‐hamster IgG (Jackson ImmunoResearch), Cy3‐ or FITC‐conjugated
anti‐rabbit IgG (Jackson ImmunoResearch), Cy3‐conjugated anti‐rat
IgG (Jackson ImmunoResearch), Cy3‐ or FITC‐conjugated anti‐goat IgG
(Jackson ImmunoResearch) or PE‐conjugated streptavidin (eBio-
science). Nuclei were stained with 40 ,6‐diamidino‐2‐phenylindole
(DAPI, Invitrogen). Then the samples were mounted in ﬂuorescent
mounting medium (DAKO) and immunoﬂuorescent images were
acquired using Zeiss LSM510 confocal ﬂuorescence microscope (Carl
Zeiss). To examine b‐galactosidase activity, the cryo‐sections were
incubated with a staining solution [2 mM magnesium chloride, 5 mM
potassium ferricyanide, 5 mM potassium ferrocyanide and 1 mg/mL
4‐chloro‐5‐bromo‐3‐indolyl‐b‐D‐galactopyranoside (X‐gal) in PBS] at
37°C for 2–12 h. To detect the hypoxic area in the uterus, Hypoxyp-
robe‐1TM (60 mg/kg, solid pimonidazole HCL; Natural Pharmacia
International) was intravenously injected 45 min before perfusion‐
ﬁxation. Then the uterus was harvested, sectioned and incubated with2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO. 1427
The paper explained
PROBLEM:
Profound neovascularization and marked vascular remodelling
and regression take place in the uterus throughout and after
pregnancy to control blood flow to the uterus as well as to the
embryo. Impairments of these fundamental processes leads to a
pregnancy failure; however, the features and regulation of these
processes are poorly defined.
RESULTS:
Here we found that dynamic and variable decidual angiogenesis
(sprouting, intussusception and networking), and active vigorous
vascular remodelling such as enlargement and elongation of
‘vascular sinus folding’ (VSF) and mural cell drop-out occur
distinctly in a spatiotemporal manner in the rapidly growing
mouse uterus during early pregnancy — just after implantation
but before placentation. Decidual angiogenesis is mainly
regulated through VEGF-A secreted from the progesterone
receptor (PR)-expressing decidual stromal cells, whereas
P4-PR-regulated VEGF-A-VEGFR2 signalling, ligand-independent
VEGFR3 signalling and uNK cells positively and coordinately
regulate enlargement and elongation of VSF. During the
postpartum period, Tie2 signalling could be involved in vascular
maturation at the endometrium in a ligand-independent
manner.
IMPACT:
Our findings indicate that two key vascular growth factor
receptors — VEGFR2 and Tie2 — strikingly but differentially
regulate decidual angiogenesis and vascular remodelling in
rapidly growing and regressing uteri. For this reason, anti-
angiogenic treatments affecting these key signalling pathways
should be prohibited during pregnancy as well as postpartum
period. In early pregnant uterus, proper enlargement and
elongation of VSF could be important for avoiding a trophoblast-
independent preeclampsia.
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1428FITC‐conjugated anti‐hypoxyprobe antibody. To detect HIF‐1a and
HIF‐2a, the antigens were retrieved in the parafﬁn‐embedded sections
by heating in a microwave for 5 min in sodium citrate solution
(10 mM; pH 6.0). After blocking, the sections were incubated overnight
at 4°C with anti‐HIF‐1a antibody (SC10790, Santa Cruz) and anti‐
HIF‐2a antibody (NB100‐122, Novus Biologicals). Then the sections
were incubated with avidin–biotin–horseradish peroxidase (HRP)
complex, and the signals were visualized with 3,30‐diaminobenzidine
(DAB) immunostaining kit (K3468, DAKO) according to the manu-
facturer’s instructions.
Morphometric analyses
Morphometric measurements of blood vessel densities and sizes in the
uteri were made on the sectioned tissues immunostained for CD31þ or
CD105þ using a photographic analysis in ImageJ software (http://rsb.
info.nih.gov/ij) or an LSM Image Browser (Carl Zeiss). For blood vessel
density, CD31þ or CD105þ blood vessel area was measured in the ULR,
CTR, AMR and total endometrium in each 0.53, 1.07, 1.56 and
3.16 mm2 area, and presented as percentage per the measured area.
Size of blood vessel was deﬁned as the longest diameter (mm) of each
CD31þ or CD105þ blood vessel at the CTR in 1.07 mm2 area, and
counted and subdivided by sizes. Numbers of vascular sprouts
(>20 mm in length) were measured in the CTR, AMR and ENP in
3–4 random 0.42 mm2 areas. Numbers of intussusception (deﬁned as
a blood vessel having pillars in the lumen) were measured in 3–4
random 0.02 mm2 areas of the endometrium. Numbers of PH3þ/
CD31þ ECs or caspase‐3þ/CD31þ ECs were measured in 3 random
0.42 mm2 areas of the endometrium.
Expressions of VEGFR2 and VEGFR3 were determined by measure-
ments of the signal densities in total endometrium of ENP, 6.5 dpc
and PD 2.5 in each 1.59, 3.16 and 0.75 mm2 area, and presented as
relative fold to the signal density of ENP that was regarded as 1. 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO.Coverage of a‐SMCþ mural cells to blood vessels was calculated
as a‐SMCþ area divided by CD31þ blood vessel area in 4 random
0.42 mm2 areas of each endometrium, and presented as percentage.
2–3 pregnant uteri per each mouse were examined, and indicated
number of mothers per each group was used for the analyses.
Scanning electron microscopy
For vascular ﬁxation, 8% paraformaldehyde was injected into left
ventricle of the mice under the anaesthesia on indicated day. The
uterine segments was ﬁxed further with 8% paraformaldehyde for
overnight, embedded with parafﬁn, and sectioned. The samples were
freeze‐dried in a lyophilizer for 24 h, andmounted on stubs and coated
with ion by ion coater (KIC‐1A, COXEM, Korea) operated at 6 mA for
60 s. Images were acquired using scanning electron microscope (SEM,
S‐4800, Hitachi, Japan) operated at 15 kV, 7 A.
Primary culture of stromal cells
DSCs at 6.5 dpc, cardiac ﬁbroblasts at P14, retinal astrocytes at P3 and
MEFs at 13.5 dpc were isolated according to procedures described
previously (Li et al, 2007; Scheef et al, 2005; Subramanian et al, 2002;
Wernig et al, 2008). Brieﬂy, each tissue was harvested, ﬁnely minced
and digested with collagenase type II (1 mg/mL; Worthington),
collagenase type IV (2 mg/mL; Worthington) and dispase II
(0.02 mg/mL; Roche Applied Science) in DMEM for 1 h at 37°C. The
digested cells were then plated onto type I collagen (BD Biosciences)‐
coated plate and were cultured in DMEM containing 10% fetal
bovine serum (FBS), streptomycin (100 mg/mL) and penicillin
(100 U/mL). The sub‐cultured cells were harvested at 48 h after
plating, and analyses for gene expressions were performed. To examine
change of VEGF‐A expression in primary cultured DSCs by P4, the cells
were starved for 6 h, and then treated with P4 (10 mM) for indicated
times.EMBO Mol Med (2013) 5, 1415–1430
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Total RNA was extracted from the uterus or the primary cultured
stromal cells using TRIzol® Reagent (Invitrogen) according to the
manufacturer’s instructions. The RNA (2 mg) was reverse transcribed
into cDNA using SuperScript II Reverse Transcriptase (Invitrogen).
Semi‐quantitative RT‐PCR was performed using NobleZymeTM Tap
(Noble Bio) with the indicated primers (see below). Quantitative
real‐time PCR was performed with the indicated primers using
Bio‐RadTM CFX96 Real‐Time PCR Detection System (Bio‐Rad). The
real‐time PCR data were analysed with Bio‐Rad CFX Manager Software
(Bio‐Rad). Primers for the semi‐quantitative RT‐PCR (Semi)
and quantitative real‐time PCR are: VEGFR2 (semi); forward 50‐
ACCAGAAGTAAAAGTGATCCCAGA ‐30 and reverse 50‐ TCCACCAAAAGATG-
GAGATAATTT ‐30 , VEGF-A (semi); forward 50‐ CAGGCTGCTCTAACGATGAA‐
30 and reverse 50‐ CAGGAATCCCAGAAACAACC‐30 , VEGF-A; forward
50‐ CAGAAGGAGAGCAGAAGTCC ‐30 and reverse 50‐ CTCCAGGGCTT-
CATCGTTA ‐30 , VEGF-C; forward 50‐ CGTTCTCTGCCAGCAACATTACCAC ‐30
and reverse 50‐ CTTGTTGGGTCCACAGACATCATGG ‐30 , PlGF; forward
50‐ CTGCTGGGAACAACTCAACAGAAGTG ‐30 and reverse 50‐ CTACAGC-
GACTCAGAAGGACACAGG ‐30 , Ang1; forward 50‐ TAGAGCTACCAACAA-
CAACAGCA ‐30 and reverse 50‐ CCCTTTAGCAAAACACCTTCTTT ‐30 , Ang2;
forward 50‐ CTGGTGAAGAGTCCAACTACAGG ‐30 and reverse 50‐ CGAA-
TCCTTTGTGCTAAAATCAC ‐30 , PDGF-A; forward 50‐ CTGCTCCTCGGC-
TGCGGATACCTC ‐30 and reverse 50‐ GAGTCGCTGGAGGTCCCGGATGCTG
‐30 , TGF-b1; forward 50‐ CAAGGAGACGGAATACAGGGCTTTC ‐30 and
reverse 50‐ GTTCATGTCATGGATGGTGCCCAG ‐30 , GAPDH; forward
50‐ GTCGTGGAGTCTACTGGTGTCTTCAC ‐30 and reverse 50‐ GTTGTCA-
TATTTCTCGTGGTTCACACCC ‐30 .
Western blotting
On the indicated days, the uterus, mammary gland, ovary, brain and
kidney were homogenized in ice‐cold buffer containing a protease
inhibitor cocktail. Each protein was separated by SDS‐PAGE gel and
transferred to PVDF membranes. After blocking with 5% skim milk, the
membranes were incubated with anti‐PR antibody (rabbit polyclonal,
Abcam) and anti‐Actin antibody (rabbit polyclonal, Sigma–Aldrich) in
blocking buffer overnight at 4°C and then with hrP‐conjugated
secondary antibody for 2 h at RT. Signals were developed with
enhanced chemiluminescence hrP substrate (Millipore) and detected
using LAS‐1000 mini (Fuji ﬁlm).
Flow cytometry
Segments of the uterus containing implanted embryos were harvested.
After removal of embryonic tissues, samples were ﬁnely minced
and digested with collagenase type II (1 mg/mL), collagenase type IV
(2 mg/mL) and dispase II (0.02 mg/mL) for 1 h at 37°C. The digested
cells were resuspended in HBSS/2% FBS at 1  106 cells per 100 mL.
The cells were incubated for 20 min with following antibodies:
PE‐conjugated anti‐mouse CD31 (clone 390, eBioscience) and FITC‐
conjugated anti‐mouse CD45 (eBioscience). After washing in HBSS/2%
FBS twice, the cells were analysed by FACS Aria II (Beckton Dickinson).
Dead cells were excluded by 7‐aminoactinomycin D (7‐AAD,
Invitrogen). Data were analysed using FlowJo software (Tree Star Inc.).
Statistical analysis
Values are presented as mean standard deviation (SD). Signiﬁcant
differences between means were determined by unpaired StudentEMBO Mol Med (2013) 5, 1415–1430 t test or analysis of variance with one‐way ANOVA followed by the
Student‐Newman‐Keuls test. Statistical signiﬁcance was set at
p < 0.01 or p < 0.05.Author contributions
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